PILHLE-001: neoadjuvant pyrotinib combined with chemotherapy in HR-positive, HER2-low (IHC 2+/FISH-negative) early breast cancer

被引：0
|
作者：
Gong, Chang
Xia, Yuan
Zhu, Yingying
Yang, Yaping
Yang, Wenqian
Chow, Louis W. C.
Ling, Li
Zeng, Yunjie
Zhong, Jiajie
Cheng, Ziliang
Shen, Jun
Lin, Qun
Zeng, Yinduo
Liu, Qiang
Song, Erwei
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO1-28-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO1-28-04
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Preclinical study and phase 2 trial of neoadjuvant pyrotinib combined with chemotherapy in luminal/HER2-low breast cancer: PILHLE-001 study
    Gong, Chang
    Xia, Yuan
    Zhu, Yingying
    Yang, Yaping
    Lin, Qun
    Liu, Qiang
    Yang, Wenqian
    Ling, Li
    Zhong, Jiajie
    Duan, Zhuxi
    Zeng, Yunjie
    Cheng, Ziliang
    Shen, Jun
    Zeng, Yinduo
    Chow, Louis Wing Cheong
    Song, Erwei
    CELL REPORTS MEDICINE, 2024, 5 (11)
  • [2] Phase II neoadjuvant pyrotinib combined with epirubicin and cyclophosphamide followed by docetaxel in HER2-low-expressing and HR-positive early or locally advanced breast cancer (PILHLE-001): A single-arm trial.
    Xia, Yuan
    Yang, Wenqian
    Yang, Ya-Ping
    Zhu, Yingying
    Zeng, Yinduo
    Qin, Tao
    Jia, Shijie
    Chen, Jiayi
    Gong, Chang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
    Shohei Shikata
    Takeshi Murata
    Masayuki Yoshida
    Hiromi Hashiguchi
    Yukiko Yoshii
    Ayumi Ogawa
    Chikashi Watase
    Sho Shiino
    Hirokazu Sugino
    Kenjiro Jimbo
    Akiko Maeshima
    Eriko Iwamoto
    Shin Takayama
    Akihiko Suto
    Scientific Reports, 13
  • [4] Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
    Shikata, Shohei
    Murata, Takeshi
    Yoshida, Masayuki
    Hashiguchi, Hiromi
    Yoshii, Yukiko
    Ogawa, Ayumi
    Watase, Chikashi
    Shiino, Sho
    Sugino, Hirokazu
    Jimbo, Kenjiro
    Maeshima, Akiko
    Iwamoto, Eriko
    Takayama, Shin
    Suto, Akihiko
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [5] HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer
    de Moura Leite, Luciana
    Cesca, Marcelle Goldner
    Tavares, Monique Celeste
    Santana, Debora Maciel
    Saldanha, Erick Figueiredo
    Guimaraes, Paula Tavares
    Sa, Daniella Dias Silva
    Simoes, Maria Fernanda Evangelista
    Viana, Rafael Lima
    Rocha, Francisca Giselle
    Loose, Simone Klog
    Silva, Sinara Figueiredo
    Pirolli, Rafaela
    Fogassa, Camilla Albina Zanco
    Mattos, Bruna Raphaeli Silva
    Campos, Fernando Augusto Batista
    Sanches, Solange Moraes
    de Lima, Vladmir Claudio Cordeiro
    Ponde, Noam Falbel
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 190 (01) : 155 - 163
  • [6] Unveiling the HER2-low phenomenon: exploring immunohistochemistry and gene expression to characterise HR-positive HER2-negative early breast cancer
    Gaudio, M.
    Jacobs, F.
    Benvenuti, C.
    Saltalamacchia, G.
    Gerosa, R.
    De Sanctis, R.
    Santoro, A.
    Zambelli, A.
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 203 (03) : 487 - 495
  • [7] HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer
    Luciana de Moura Leite
    Marcelle Goldner Cesca
    Monique Celeste Tavares
    Debora Maciel Santana
    Erick Figueiredo Saldanha
    Paula Tavares Guimarães
    Daniella Dias Silva Sá
    Maria Fernanda Evangelista Simões
    Rafael Lima Viana
    Francisca Giselle Rocha
    Simone Klog Loose
    Sinara Figueiredo Silva
    Rafaela Pirolli
    Camilla Albina Zanco Fogassa
    Bruna Raphaeli Silva Mattos
    Fernando Augusto Batista Campos
    Solange Moraes Sanches
    Vladmir Cláudio Cordeiro de Lima
    Noam Falbel Pondé
    Breast Cancer Research and Treatment, 2021, 190 : 155 - 163
  • [8] Unveiling the HER2-low phenomenon: exploring immunohistochemistry and gene expression to characterise HR-positive HER2-negative early breast cancer
    M. Gaudio
    F. Jacobs
    C. Benvenuti
    G. Saltalamacchia
    R. Gerosa
    R. De Sanctis
    A. Santoro
    A. Zambelli
    Breast Cancer Research and Treatment, 2024, 203 : 487 - 495
  • [9] Clinical outcomes of neoadjuvant chemotherapy in HER2-low early breast cancer
    Gudelj, Dora
    Cular, Katarina
    Toula, Lea
    Krizic, Marija
    Popovic, Marina
    Plavetic, Natalija Dedic
    Kelecic, Ana
    Ivanac, Gordana
    Soce, Majana
    Gjergjaj, Iva Kukal
    Silovski, Tajana
    CANCER RESEARCH, 2024, 84 (09)
  • [10] Ribociclib in HR-positive, HER2-negative breast cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2016, 17 (11): : E482 - E482
12345